$86.19
0.48% yesterday
NYSE, Dec 05, 10:07 pm CET
ISIN
US28176E1082
Symbol
EW

Edwards Lifesciences Stock price

$86.19
+3.35 4.04% 1M
+8.42 10.83% 6M
+12.16 16.43% YTD
+13.76 19.00% 1Y
+12.34 16.71% 3Y
+0.13 0.15% 5Y
+59.39 221.62% 10Y
+82.71 2,377.29% 20Y
NYSE, Closing price Fri, Dec 05 2025
+0.41 0.48%

New AI Insights on Edwards Lifesciences Insights AI Insights on Edwards Lifesciences

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Key metrics

Basic
Market capitalization
$50.0b
Enterprise Value
$46.8b
Net debt
positive
Cash
$3.8b
Shares outstanding
580.7m
Valuation (TTM | estimate)
P/E
37.0 | 32.8
P/S
8.5 | 8.1
EV/Sales
8.0 | 7.5
EV/FCF
58.5
P/B
4.9
Financial Health
Equity Ratio
76.6%
Return on Equity
41.8%
ROCE
14.0%
ROIC
15.7%
Debt/Equity
0.1
Financials (TTM | estimate)
Revenue
$5.9b | $6.2b
EBITDA
$1.8b | $1.8b
EBIT
$1.6b | $1.7b
Net Income
$1.4b | $1.5b
Free Cash Flow
$799.6m
Growth (TTM | estimate)
Revenue
4.7% | 14.0%
EBITDA
4.7% | 12.3%
EBIT
4.7% | 13.0%
Net Income
-67.1% | -63.4%
Free Cash Flow
67.7%
Margin (TTM | estimate)
Gross
78.2%
EBITDA
30.4% | 29.6%
EBIT
27.7%
Net
23.3% | 24.7%
Free Cash Flow
13.6%
More
EPS
$2.3
FCF per Share
$1.4
Short interest
1.9%
Employees
16k
Rev per Employee
$340.0k
Show more

Is Edwards Lifesciences a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,088 stocks worldwide.

Edwards Lifesciences Stock Analysis

Unlock Scores for Free

Analyst Opinions

42 Analysts have issued a Edwards Lifesciences forecast:

29x Buy
69%
13x Hold
31%

Analyst Opinions

42 Analysts have issued a Edwards Lifesciences forecast:

Buy
69%
Hold
31%

Financial data from Edwards Lifesciences

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
5,884 5,884
5% 5%
100%
- Direct Costs 1,283 1,283
7% 7%
22%
4,600 4,600
4% 4%
78%
- Selling and Administrative Expenses 1,974 1,974
11% 11%
34%
- Research and Development Expense 1,083 1,083
3% 3%
18%
1,788 1,788
5% 5%
30%
- Depreciation and Amortization 157 157
5% 5%
3%
EBIT (Operating Income) EBIT 1,632 1,632
5% 5%
28%
Net Profit 1,368 1,368
67% 67%
23%

In millions USD.

Don't miss a Thing! We will send you all news about Edwards Lifesciences directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Edwards Lifesciences Stock News

Neutral
Business Wire
2 days ago
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) will outline its patient-focused strategy and share financial guidance during its annual investor conference. Entering 2026 with momentum for sustainable differentiated growth, Edwards is uniquely positioned with leading therapies across its core structural heart innovations for patients with aortic stenosis (AS), mitral regurgita...
Neutral
PRNewsWire
6 days ago
Shareholders should contact the firm immediately as there may be limited time to enforce your rights. NEW YORK , Nov. 30, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Edwards Lifesciences Corporation (NYSE: EW) breached their fiduciary duties to shareholders.
Positive
Seeking Alpha
16 days ago
The portfolio generated a modestly positive absolute return in Q3, but it trailed the MSCI All Country World Small Mid Index. The Q3 underperformance was driven by stock selection in the IT, financials and consumer discretionary sectors. On the positive side, stock selection in the health care and industrials sectors was the strongest contributor to performance.
More Edwards Lifesciences News

Company Profile

Edwards Lifesciences Corp. engages in the patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into three areas: Transcatheter Heart Valves, Surgical Structural Heart and Critical Care. The Transcatheter Heart Valves portfolio includes technologies designed to treat heart valve disease using catheter-based approaches as opposed to open surgical techniques. Its portfolio includes technologies designed for nonsurgical replacement of heart valves. The Surgical Structural Heart portfolio includes tissue heart valves and heart valve repair products for the surgical replacement or repair of a patient's heart valve. The Critical Care portfolio products through hemodynamic monitoring system measures a patient's heart function and fluid status in surgical and intensive care settings. The company was founded by Miles Lowell Edwards in 1958 and is headquartered in Irvine, CA.

Head office United States
CEO Bernard Zovighian
Employees 15,800
Founded 1958
Website www.edwards.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today